Nuvation Bio Hits $23.2M in Q2 2026 IBTROZI Revenue, Eyes 2029 PFS Data
NUVB reports 25% quarter-over-quarter growth in IBTROZI sales, becoming ROS1 TKI market leader in first-line therapy. Nuvation Bio reported IBTROZI net revenue of $23.2 million for Q2 2026, a 25% increase quarter-over-quarter. The company added approximately 160 new patien